Frontlight ResearchEarly access
Not yet taking people in United StatesPhase 1/2
A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Key facts
- Who runs it
- Bristol-Myers Squibb
- Where
- San Antonio and West Valley City, United StatesSee the 2 sitesAlso in 1 other country, 2 sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 171 people, planned
- Starts
- 30 Nov 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 4 groups
- Treatments tested
- BMS-986548
- Cetuximab
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification)
- Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Participants must have measurable disease assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Participants should have previously received, be ineligible for, or decline (after having been provided adequate information to make an informed decision) the following Standard of Care (SoC) treatments:; Part 1A: All appropriate SoC treatments for the disease under study
- Part 2A:,
- Non-Small Cell Lung Cancer (NSCLC): platinum-based doublet chemotherapy and/or PD-(L)1 checkpoint inhibitor
- Colorectal Cancer (CRC): fluoropyrimidine, oxaliplatin, and/or irinotecan-based chemotherapy, and Vascular Endothelial Growth Factor (VEGF)-targeted antibodies. For participants with dMMR/Microsatellite Instability-High (MSI-H) (or POLE/POLD1 mutation) CRC, a checkpoint inhibitor (PD-[L]1 and/or CTLA-4)
- Pancreatic Ductal Adenocarcinoma (PDAC): fluoropyrimidine-based chemotherapy with oxaliplatin and irinotecan (may include liposomal formulation) and/or gemcitabine-based chemotherapy with albumin-bound paclitaxel or cisplatin
- Part 1B, Part 2B:,
- CRC: fluoropyrimidine, oxaliplatin, and/or irinotecan-based chemotherapy, and VEGF-targeted antibodies. For participants with dMMR/MSI-H (or POLE/POLD1 mutation) CRC, a checkpoint inhibitor (PD-[L]1 and/or CTLA-4)
Who cannot take part
- Participants must not have had prior treatment with a (K)RAS directed therapy including approved treatments and investigational agents
- Participants must not have a history of prior Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
- Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment
- Participants must not have a history of (non-infectious) Interstitial Lung Disease (ILD)/pneumonitis requiring steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
- Participants must not have untreated central nervous system (CNS) metastases
- Other protocol-defined Inclusion/Exclusion criteria apply
Where in United States
Also in 1 other country, 2 sites
- San Antonio, TexasHospital not named in the registryContact: Site 0001Not yet recruiting
- West Valley City, UtahHospital not named in the registryContact: Site 0004Not yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to assess the safety, tolerability, efficacy, and drug levels of BMS-986548 as a monotherapy and in combination with anti-cancer agents in participants with advanced solid malignancies.
The 4 groups in the trial
- Part 1A Monotherapy Dose Escalation: BMS-986548Treatment being tested
Treatment: BMS-986548
- Part 1B Combination Dose Escalation: BMS-986548 + CetuximabTreatment being tested
Treatment: BMS-986548 and Cetuximab
- Part 2A Monotherapy Dose Expansion: BMS-986548Treatment being tested
Treatment: BMS-986548
- Part 2B Combination Dose Expansion: BMS-986548 + CetuximabTreatment being tested
Treatment: BMS-986548 and Cetuximab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986548 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- Record updated
- 16 November 2026